Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05971329




Registration number
NCT05971329
Ethics application status
Date submitted
18/07/2023
Date registered
2/08/2023

Titles & IDs
Public title
Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease
Scientific title
Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease
Secondary ID [1] 0 0
ZG-2022-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Radiculopathy, Cervical 0 0
Myelopathy Cervical 0 0
Neurological Abnormality 0 0
Disc Disease 0 0
Disc Degeneration 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Cervical Fusion (ZetaFuse™ Bone Graft)

Experimental: Pilot Study of ZetaFuse Bone Graft for the Treatment of Cervical Degenerative Disc Disease - Involves the use of a medical device. The prepared ZetaFuse Bone Graft is packed into the hollow space of a PEEK interbody before surgical implantation.


Treatment: Devices: Cervical Fusion (ZetaFuse™ Bone Graft)
Fusion of the C3-C7 cervical vertebral bodies
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Subjects with Radiologic Determination of Bone Fusion of the Treated Cervical Vertebral Bones
Timepoint [1] 0 0
1 year post surgery
Secondary outcome [1] 0 0
Quality of Life via Short Form (SF12v2) Health Survey
Timepoint [1] 0 0
1 year post surgery

Eligibility
Key inclusion criteria
1. Age 22 to 75 years (inclusive) at the time of enrollment.
2. Diagnosis of radiculopathy and/or myelopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:

* Neck and/or arm pain (at least 3 on the 0 - 10 numeric rating scale for pain.
* Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
* Abnormal sensation including hyperesthesia or hypoesthesia. and/or
* Abnormal reflexes.
3. Symptomatic at two contiguous levels from C3 to C7.
4. Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:

* Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.
* Degenerative spondylosis on CT or MRI.
* Disc herniation on CT or MRI.
5. Neck Disability Index Score = 30/100.
6. Unresponsive to non-operative treatment (e.g., rest, heat, physical therapy, chiropractor, massage, pain medication) for approximately six weeks from the symptom onset; or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management.
7. No previous surgical intervention at the involved levels or any subsequent, planned/staged surgical procedure at the involved or adjacent levels.
8. Appropriate for treatment using an anterior surgical approach.
9. Skeletally mature at the time of the surgery.
10. Medically cleared for surgery.
11. If a female of child-bearing potential, subject is non-pregnant, nonnursing, and agrees not to become pregnant during the study period.
12. Willing and able to comply with the study plan.
13. Signed written Patient Informed Consent Form.
14. Willing to discontinue use of non-steroidal anti-inflammatory drugs (NSAIDs) from one week before the surgery to 3 months after the surgery.
Minimum age
22 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. A cervical spinal condition other than symptomatic cervical degenerative disc disease requiring surgical treatment at the involved levels.
2. Documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing sagittal plane translation >3.5 mm or sagittal plane angulation > 20°.
3. More than two cervical levels requiring surgical treatment.
4. An immobile or spontaneously fused level adjacent to the levels to be treated.
5. Severe pathology of the facet joints of the involved vertebral bodies.
6. Previous surgical intervention at either one or both of the involved levels or at adjacent levels.
7. History of trauma to the C3 to C7 levels resulting in significant bony or disco-ligamentous cervical spine injury.
8. Previously diagnosed with osteomalacia;
9. Any of the following that may be associated with an increased risk osteoporosis (if "Yes" to any of the below risk factors, a DEXA Scan is required to determine eligibility). If the level of bone mineral density (BMD) on DEXA scan is a T score of -2.5 or worse (i.e., -2.6, - 2.7, etc.) the subject is ineligible for the study.

* Postmenopausal non-Black female over 60 years of age who weighs less than 140 pounds.
* Postmenopausal female who has sustained a non-traumatic hip, spine, or wrist fracture.
* Male over the age of 60 who has sustained a non-traumatic hip or spine fracture.
* Taking bisphosphonate medication for the treatment of osteoporosis.
* Chronic use of high dose steroids.
10. Reported active malignancy that included a history of any invasive malignancy (except non-melanoma skin cancer) unless the subject had been treated with curative intent and there had been no clinical signs or symptoms of the malignancy for at least five years.
11. Overt or active systemic infection, or infection at the operative site.
12. Insulin dependent diabetes.
13. A tobacco user who does not agree to suspend smoking prior to surgery.
14. Chronic or acute renal failure or prior history of renal disease.
15. Mentally incompetent (If questionable, obtain psychiatric consult).
16. A prisoner.
17. An alcohol and/or drug abuser currently or recently undergoing treatment for alcohol and/or drug abuse.
18. Involved with current or pending litigation regarding a spinal condition.
19. Received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate) excluding routine perioperative anti-inflammatory drugs.
20. A history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers- Danlos Syndrome, or osteogenesis imperfecta).
21. A condition that requires post-operative medications that interfere with the stability of the implant, such as steroids. (This does not include low dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs).
22. Received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation with the ZetaFuse™ Bone Graft device.

Study design
Purpose of the study
Other
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/09/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2025
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Prince of Wales Private Hospital - Randwick
Recruitment hospital [2] 0 0
Prince of Wales Public Hospital - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Zetagen Therapeutics, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Julie Croft
Address 0 0
Country 0 0
Phone 0 0
0882494788
Fax 0 0
Email 0 0
julie.croft@avancecro.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05971329